Interleukin-6 induces drug resistance in renal cell carcinoma-Reference-Cited by-同舟云学术

Interleukin-6 induces drug resistance in renal cell carcinoma

Published:2018 Issue:3 Volume:64 Page:103-110
ISSN:0016-2590
Container-title:FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
language:en
Short-container-title:FJMS

Author:

Ishibashi Kei¹,Koguchi Tomoyuki¹,Matsuoka Kanako¹,Onagi Akifumi¹,Tanji Ryo¹,Takinami-Honda Ruriko¹,Hoshi Seiji¹,Onoda Mitsutaka¹,Kurimura Yoshimasa¹,Hata Junya¹,Sato Yuichi¹,Kataoka Masao¹,Ogawsa Soichiro¹,Haga Nobuhiro¹,Kojima Yoshiyuki¹

Affiliation:

1. Department of Urology, Fukushima Medical University School of Medicine

Publisher

The Fukushima Society of Medical Science

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/fms/64/3/64_2018-15/_pdf

Reference61 articles.

1. 1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med, 353(23): 2477-2490, 2005.

2. 2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356(2): 125-134, 2007.

3. 3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356(2): 115-124, 2007.